Asia Pacific
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Zhongshan-based biopharma company Akeso will await the verdict of the Chinese medicines regulator on a penpulimab-based combo therapy. 22 November 2024
Pharmaceutical
Shanghai-based Zai Lab and New York’s Pfizer are to work together on the commercialization of Xacduro (sulbactam-durlobactam) in China. 22 November 2024
Biotechnology
Hong Kong-based Sino Biopharm has signed an equity investment and strategic collaboration agreement with LaNova Medicines, advancing its oncology focus. 22 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Pharmaceutical
Anglo-Austrian firm F2G Ltd has entered a strategic collaboration with Japan’s Shionogi to develop and commercialize the new antifungal agent olorofim for invasive fungal infections in Europe and Asia. 16 May 2022
Pharmaceutical
Japanese drugmaker Takeda has announced the Indian launch of Adynovate, an extended half-life recombinant Factor VIII (rFVIII) treatment, using established technology (controlled PEGylation), for hemophilia A patients. 16 May 2022
Pharmaceutical
Japanese drugmaker Otsuka says it has decided to terminate its global license agreements with Akebia Therapeutics for vadadustat, under development as an oral treatment for anemia associated with chronic kidney disease (renal anemia). 16 May 2022
Pharmaceutical
The US Food and Drug Administration has approved Radicava ORS (edaravone) oral suspension for the treatment of adults with amyotrophic lateral sclerosis (ALS). 13 May 2022
Pharmaceutical
Japanese ophthalmology specialist Santen Pharmaceutical has received approval of Verkazia (ciclosporin eye drops) from the National Medical Products Administration (NMPA) in China through its Chinese legal entity for the treatment of severe vernal keratoconjunctivitis (VKC) in children and adolescents aged 4 years and above. 11 May 2022
Biotechnology
Alzheimer’s drug developer Eisai has completed a rolling submission to the US Food and Drug Administration for its next-gen anti-amyloid beta candidate lecanemab. 10 May 2022
Biotechnology
Takeda Pharmaceutical has provided an update on an initiative for improving early access to treatments for rare diseases in India. 9 May 2022
Biotechnology
Sino-American biotech BeiGene has announced that the China National Medical Products Administration (NMPA) has granted conditional approval of Blincyto (blinatumomab) for injection for the treatment of pediatric patients with relapsed or refractory (R/R) CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). 6 May 2022
Pharmaceutical
Finnish drugmaker Orion Corp has announced an agreement with China’s Jemincare. 6 May 2022
Pharmaceutical
Ireland-headquartered drugmaker Jazz Pharmaceuticals and Japan’s Sumitomo Pharma have announced that the companies have entered into an exclusive licensing agreement. 5 May 2022
Biotechnology
Singapore-based Juniper Biologics and privately-held Swiss drugmaker Helsinn Group have signed an exclusive license agreement to develop and commercialize infigratinib (INN) in Australia, New Zealand, Southeast Asia and certain markets in the Middle East and Africa . 4 May 2022
Pharmaceutical
Biotechnology Innovation Organization (BIO) has hit out at the US Trade Representative’s (USTR) continued support for a waiver of IP protections for COVID-19 vaccines under the WTO (World Trade Organization) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). 3 May 2022
Pharmaceutical
Chinese biotech Hutchmed on Monday announced that the US Food and Drug Administration has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for surufatinib for the treatment of pancreatic (pNETs) and extra-pancreatic (non-pancreatic, epNETs) neuroendocrine tumors (NETs). 3 May 2022
Biotechnology
Chinese start-up Xbiome, an AI-based microbiome drug development company, has acquired the clinical-stage M201 program from Californian firm Assembly Biosciences. 27 April 2022
Biotechnology
The China National Medical Products Administration (NMPA) has recently granted breakthrough therapy (BTD) designation to China’s Innovent Biologic’s IBI310 in combination with Tyvyt (sintilimab) to treat patients with recurrent or metastatic cervical cancer. 27 April 2022
Biotechnology
Japanese drugmaker Eisai today announced an article about long-term health outcomes of its investigational anti-amyloid-beta protofibril antibody lecanemab in people living with early Alzheimer’s disease (AD) using simulation modeling was published in a peer-reviewed journal Neurology and Therapy. 27 April 2022
Biotechnology
The Malaysian business of Biocon subsidiary Biocon Biologics has agreed a deal to supply its recombinant human insulin brand Insugen to the country’s healthcare system. 26 April 2022
Biotechnology
Japan’s Sumitomo Pharma, formerly known as Sumitomo Dainippon Pharma, says it has decided to construct a cGMP-compliant cell processing center (CPC) in the USA. 22 April 2022
Pharmaceutical
Japanese drugmaker Astellas Pharma has announced that it will book an impairment loss in both the fourth quarter of the fiscal year ended on March 31, and in the subsequent quarter. 22 April 2022
Biotechnology
Top-line data for an mRNA-based COVID-19 vaccine from Arcturus Therapeutics have failed to impress investors, with the firm reporting 55% efficacy in the prevention of symptomatic disease. 21 April 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze